Distigmine

Chemical compound
  • N07AA03 (WHO)
Pharmacokinetic dataBioavailability4.65% [1]Elimination half-life65 h [1]Excretionrenal [1]Identifiers
  • (1-methylpyridin-1-ium-3-yl) N-methyl-N-{6-[methyl-
    (1-methylpyridin-1-ium-3-yl)oxycarbonylamino]
    hexyl}carbamate dibromide
CAS Number
  • 17299-00-2 checkY
  • bromide: 15876-67-2 checkY
PubChem CID
  • 27522
ChemSpider
  • 25613 checkY
UNII
  • T940307O7B
  • bromide: 750F36OP6J checkY
KEGG
  • D01228 ☒N
ChEBI
  • CHEBI:31512
ChEMBL
  • ChEMBL1098285 checkY
CompTox Dashboard (EPA)
  • DTXSID60935985 Edit this at Wikidata
ECHA InfoCard100.036.360 Edit this at WikidataChemical and physical dataFormulaC22H32Br2N4O4Molar mass576.330 g·mol−13D model (JSmol)
  • Interactive image
  • [Br-].[Br-].O=C(Oc1ccc[n+](c1)C)N(CCCCCCN(C(=O)Oc2ccc[n+](c2)C)C)C
InChI
  • InChI=1S/C22H32N4O4.2BrH/c1-23-13-9-11-19(17-23)29-21(27)25(3)15-7-5-6-8-16-26(4)22(28)30-20-12-10-14-24(2)18-20;;/h9-14,17-18H,5-8,15-16H2,1-4H3;2*1H/q+2;;/p-2 checkY
  • Key:GJHSNEVFXQVOHR-UHFFFAOYSA-L checkY
 ☒NcheckY (what is this?)  (verify)

Distigmine (as distigmine bromide) is a parasympathomimetic. Distigmine is similar to pyridostigmine and neostigmine but has a longer duration of action. It is available as tablets on prescription only. It is commonly used to treat various conditions, including myasthenia gravis and underactive bladder.[2] Distigmine has a greater risk of causing cholinergic crisis because of accumulation of the drug being more likely than with neostigmine or pyridostigmine and so distigmine is rarely used as a treatment for myasthenia gravis, unlike pyridostigmine and neostigmine.

References

  1. ^ a b c "Distigmine" (PDF). The Japanese Pharmacopoeia. Official Monographs (14/I ed.). Tokyo: Yakuji Nippo. Ltd. 2001. p. 599. ISBN 978-4-8408-0672-5.
  2. ^ Moro C, Phelps C, Veer V, Clark J, Glasziou P, Tikkinen KA, Scott AM (November 2021). "The effectiveness of parasympathomimetics for treating underactive bladder: A systematic review and meta-analysis" (PDF). Neurourology and Urodynamics. 41 (1): 127–139. doi:10.1002/nau.24839. PMID 34816481. S2CID 244530010.
  • v
  • t
  • e
Enzyme
(modulators)
ChATTooltip Choline acetyltransferase
  • Inhibitors: 1-(-Benzoylethyl)pyridinium
  • 2-(α-Naphthoyl)ethyltrimethylammonium
  • 3-Chloro-4-stillbazole
  • 4-(1-Naphthylvinyl)pyridine
  • Acetylseco hemicholinium-3
  • Acryloylcholine
  • AF64A
  • B115
  • BETA
  • CM-54,903
  • N,N-Dimethylaminoethylacrylate
  • N,N-Dimethylaminoethylchloroacetate
AChETooltip Acetylcholinesterase
BChETooltip Butyrylcholinesterase
Transporter
(modulators)
CHTTooltip Choline transporter
VAChTTooltip Vesicular acetylcholine transporter
Release
(modulators)
Inhibitors
  • SNAP-25Tooltip Synaptosomal-associated protein 25 inactivators: Botulinum toxin (A, C, E)
  • VAMPTooltip Vesicle-associated membrane protein inactivators: Botulinum toxin (B, D, F, G)
Enhancers
See also
Receptor/signaling modulators
Muscarinic acetylcholine receptor modulators
Nicotinic acetylcholine receptor modulators
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e